Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 20/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | EIF2AK2 | P19525 | 2/20 | 0.45 |
| ▸ | EIF2AK1 | Q9BQI3 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30544150 | 0.83 | EIF2AK3 (0.62) | EIF2AK3 | |
| SCHEMBL19743322 | 0.83 | EIF2AK3 (0.62) | EIF2AK3 | |
| Hydrochloric Acid SCHEMBL19743287 | 0.82 | EIF2AK3 (0.61) | EIF2AK3 | |
| SCHEMBL19743553 | 0.81 | EIF2AK3 (0.52) | EIF2AK3 | |
| SCHEMBL20351494 | 0.77 | EIF2AK3 (0.52) | EIF2AK3RIPK1 | |
| SCHEMBL20351783 | 0.76 | RIPK2 (0.61) | EIF2AK3EIF2AK4 | |
| SCHEMBL20351663 | 0.76 | EIF2AK3 (0.50) | EIF2AK3RIPK1 | |
| SCHEMBL20351734 | 0.76 | SRC (0.49) | EIF2AK3CYP3A4EIF2AK2EIF2AK1RIPK1 | |
| SCHEMBL20351577 | 0.76 | EIF2AK3 (0.50) | EIF2AK3RIPK1 | |
| SCHEMBL30582589 | 0.75 | AXL (0.63) | EIF2AK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356186-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | HIBERCELL, INC. | 2022-11-10 | — | — | US | disclosed |
| WO-2021041975-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356186-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | EEF2K, ATF4, MAPKAPK2 | EIF2AK3 96/4885CYP3A4 3991/4885EIF2AK2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.